Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy

NCT00157508 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Early Nephropathy

Interventions

DRUG: nitroaspirin

Sponsor

Mario Negri Institute for Pharmacological Research